Tetra Therapeutics today announced that it has entered into a definitive merger agreement for Shionogi & Co., Ltd. to acquire Tetra. With this acquisition, Shionogi will obtain global rights to Tetra’s entire portfolio of compounds for the treatment of brain disorders associated with cognitive and memory deficits, notably BPN14770, a selective inhibitor of phosphodiesterase‐4D (PDE4D).
The two companies entered into a collaboration and investment agreement in 2018 and earlier this year announced an expanded alliance to develop and commercialize BPN14770 for the treatment of Alzheimer’s disease (AD), Fragile X syndrome (FXS) and other indications. Currently, Tetra is conducting a Phase II study in FXS and recently completed a Phase II study in AD in the United States.
“With over a decade of research, development and investment, Tetra has demonstrated the unique ability of allosteric inhibitors of phosphodiesterase-4D (PDE4D) to deliver disease-modifying potential in central nervous system (CNS) disorders,” said Mark Gurney, Ph.D., Chairman and Chief Executive Officer of Tetra Therapeutics. “Shionogi has been a valued partner for the last two and half years, and with the company’s development and commercialization expertise, we believe Shionogi is ideally positioned to bring the potential of our platform to patients and provide new treatment options within these areas of urgent medical need. This is a great outcome for our investors and stakeholders.”
“We are excited to combine Tetra’s portfolio with our drug development capabilities to further advance BPN14770 in CNS disorders, including AD and FXS,” said Dr. Isao Teshirogi, President and Chief Executive Officer, Shionogi & Co., Ltd. “Tetra’s deep level of drug discovery know-how in the CNS area will help us to solve for the cognitive disorders our ageing population is facing, and we believe we are well-positioned to bring BPN14770 to patients in need.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Under the terms of the merger agreement, Tetra will become a wholly owned subsidiary of Shionogi, and Shionogi will have global rights to BPN14770 and all Tetra compounds. Based on the achievement of certain predetermined regulatory and commercial milestones the total transaction value may be up to $500 million.
Source: BioSpace